Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 20;12(11):1372.
doi: 10.3390/pathogens12111372.

Pediatric Drug-Resistant Tuberculosis: The Current and Future Prospects for Management and Prevention

Dhanya Dharmapalan  1 , Sushant Satish Mane  2
Affiliations
Review

Pediatric Drug-Resistant Tuberculosis: The Current and Future Prospects for Management and Prevention

Dhanya Dharmapalan et al. Pathogens. .

Abstract

In the continued battle against one of the oldest enemies known to mankind, Mycobacterium tuberculosis (MTB), the emergence of drug resistance to antituberculosis drugs among children poses multiple challenges for early detection and treatment. Molecular diagnostics and newer drugs like bedaquiline and delamanid have strengthened the armamentarium and helped design convenient, safe, and child-friendly therapeutic regimens against drug-resistant tuberculosis (TB). Preventive strategies like treatment of TB infection among children living in close contact with patients with drug-resistant TB and effective vaccines against TB are currently in the investigative stages of development and implementation. In addition to the implementation of recent novel diagnostics and treatment modalities, effective psychosocial and nutritional support, as well as dedicated monitoring for compliance and adverse effects, are crucial determinants for successful treatment outcomes in these children.

Keywords: TB infection; TB preventive treatment; TB vaccines; Xpert MTB; bedaquiline (BDQ); delamanid (DLM); latent TB; tuberculosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. International Union Against Tuberculosis and Lung Disease . Diagnostic CXR Atlas for Tuberculosis in Children: A Guide to Chest X-ray Interpretation. 2nd ed. International Union Against Tuberculosis and Lung Disease; Paris, France: 2022.
    1. Dunn J.J., Starke J.R., Revell P.A. Laboratory Diagnosis of Mycobacterium tuberculosis Infection and Disease in Children. J. Clin. Microbiol. 2016;54:1434–1441. doi: 10.1128/JCM.03043-15. - DOI - PMC - PubMed
    1. Seddon J.A., Johnson S., Palmer M., van der Zalm M.M., Lopez-Varela E., Hughes J., Schaaf H.S. Multidrug-Resistant Tuberculosis in Children and Adolescents: Current Strategies for Prevention and Treatment. Expert. Rev. Respir. Med. 2021;15:221–237. doi: 10.1080/17476348.2021.1828069. - DOI - PubMed
    1. Cohen K.A., Manson A.L., Desjardins C.A., Abeel T., Earl A.M. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: Progress, promise, and challenges. Genome Med. 2019;11:45. doi: 10.1186/s13073-019-0660-8. - DOI - PMC - PubMed
    1. Ramaswamy S., Musser J.M. Molecular Genetic Basis of Antimicrobial Agent Resistance in Mycobacterium Tuberculosis: 1998 Update. Tuber. Lung Dis. 1998;79:3–29. doi: 10.1054/tuld.1998.0002. - DOI - PubMed

LinkOut - more resources